| GRZASKO, Norbert, Marek HUS, Sylwia CHOCHOLSKA, Andrzej PLUTA, Roman HÁJEK a Anna DMOSZYNSKA. 1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens. Leukemia & lymphoma. England: Informa Healthcare, 2012, roč. 53, č. 12, s. 2500-2503. ISSN 1042-8194. Dostupné z: https://dx.doi.org/10.3109/10428194.2012.684349. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1087249,
author = {Grzasko, Norbert and Hus, Marek and Chocholska, Sylwia and Pluta, Andrzej and Hájek, Roman and Dmoszynska, Anna},
article_location = {England},
article_number = {12},
doi = {http://dx.doi.org/10.3109/10428194.2012.684349},
keywords = {In-Situ Hybridization; Expression; Chromosome-1; Survival; Model},
language = {eng},
issn = {1042-8194},
journal = {Leukemia & lymphoma},
title = {1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens},
url = {http://informahealthcare.com/doi/abs/10.3109/10428194.2012.684349},
volume = {53},
year = {2012}
}
TY - JOUR
ID - 1087249
AU - Grzasko, Norbert - Hus, Marek - Chocholska, Sylwia - Pluta, Andrzej - Hájek, Roman - Dmoszynska, Anna
PY - 2012
TI - 1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens
JF - Leukemia & lymphoma
VL - 53
IS - 12
SP - 2500-2503
EP - 2500-2503
PB - Informa Healthcare
SN - 10428194
KW - In-Situ Hybridization
KW - Expression
KW - Chromosome-1
KW - Survival
KW - Model
UR - http://informahealthcare.com/doi/abs/10.3109/10428194.2012.684349
N2 - In this study we assessed the prognostic value of amp(1q21) alone and in combination with del(17p13), del(13q14) and t(4,14)(p16;q32) detected by fl uorescence in situ hybridization(FISH) in newly diagnosed patients with MM treated with thalidomide-based induction regimens. Th e primary endpoints were response rate after fi rst-line therapy, PFS and OS.
ER -
GRZASKO, Norbert, Marek HUS, Sylwia CHOCHOLSKA, Andrzej PLUTA, Roman HÁJEK a Anna DMOSZYNSKA. 1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens. \textit{Leukemia \&{} lymphoma}. England: Informa Healthcare, 2012, roč.~53, č.~12, s.~2500-2503. ISSN~1042-8194. Dostupné z: https://dx.doi.org/10.3109/10428194.2012.684349.
|
